Hutchmed's lung cancer drug included in China's NRDL

18 January 2023

Negotiations with the China National Healthcare Security Administration (NHSA) have borne fruit for Hutchmed (HKEX:13) and its product Orpathys (savolitinib).

The oral, potent and highly selective MET tyrosine kinase inhibitor has been included in China’s updated National Reimbursement Drug List (NRDL) to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy.

"The only targeted medicine approved in this setting and who often do not respond well to chemotherapy"Orpathys received conditional approval in this indication in China in June 2021. It was jointly developed by AstraZeneca (LSE: AZN) and Hutchmed, with the Chinese biopharma taking the lead in China and worldwide commercialization led by the Anglo-Swedish pharma major.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK